ORGANIZATION

Savings from Off-Year Drug Re-Pricing Should Go Towards Medical Fees: JMA Chief

By Takashi Ohama July 15, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

As Japan gears up for full debates on next year’s “off-year” drug re-pricing, Kichiro Matsumoto, new president of the Japan Medical Association (JMA), renewed the group’s call on July 14 for directing savings from such price cuts towards boosting physician…

To read the full story

Pharma Eyes Riveted on JMA’s Stance on Off-Year Revision as New Chief Builds Ties with Govt
August 22, 2022
Kichiro Matsumoto Elected as New Chief of Japan Medical Association
June 27, 2022

ORGANIZATION

EFPIA Japan, Patient Groups Call for Stronger Health Literacy, PPI
December 22, 2025
JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
December 18, 2025
Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…